8-K: Rayonier Advanced Materials Announces Strong Q4 and Full Year 2024 Results, Provides 2025 Guidance

Rayonier Advanced Materials (RYAM) reports improved financial performance for 2024, driven by strategic shifts and provides Adjusted EBITDA guidance of $215 million to $235 million for 2025.

Summary

• Rayonier Advanced Materials (RYAM) reported its fourth quarter and full year 2024 financial results.
• Net sales for 2024 were $1,630 million, a slight decrease of $13 million from the previous year.
• The company's loss from continuing operations improved significantly to $42 million, a $60 million improvement year-over-year.
• Adjusted EBITDA from continuing operations increased by $83 million to $222 million for 2024.
• RYAM reduced its exposure to commodity markets, decreasing commodity sales from 22% in 2023 to 13% in 2024.
• The company secured $67 million in capital commitments for its biomaterials strategy, valuing these investments at approximately $180 million.
• RYAM refinanced the majority of its debt with a new five-year loan, providing financial flexibility.
• For 2025, the company anticipates Adjusted EBITDA between $215 million and $235 million and Adjusted Free Cash Flow between $25 million and $45 million.
• The company expects to achieve $10 million in production efficiencies in 2025 through strategic capital investments and continuous improvement initiatives.
• RYAM expects headwinds in its Paperboard business due to new supply and certain one-time benefits in 2024, along with the impact of a 25% tariff on U.S. sales of paperboard.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting improved financial performance and strategic initiatives. However, it also acknowledges potential headwinds and risks, preventing a higher score.

Positives

• Significant improvement in Adjusted EBITDA and free cash flow.
• Successful debt refinancing provides financial stability.
• Strategic shift towards higher-value cellulose specialties and biomaterials.
• Secured capital commitments for biomaterials investments.
• Negotiated price increases for cellulose specialties.
• Reduction in exposure to commodity markets.
• The company generated operating cash flows of $203 million during the year ended December 31, 2024.

Negatives

• Slight decrease in net sales compared to the prior year.
• Anticipated headwinds in the Paperboard business due to new supply and tariffs.
• The company reported a net loss of $39 million for the year ended December 31, 2024.
• The company expects to incur net custodial site costs totaling $20 million to $22 million in 2025.
• High-Yield Pulp EBITDA is expected to approximate a loss of $14 million for the full year 2025.

Risks

• Potential for additional tariffs across business segments.
• Impact of new supply in the Paperboard market.
• Uncertainty regarding the Fernandina Beach bioethanol facility project due to site plan denial.
• The potential long-term impact of climate-related risks remain uncertain.
• The company is subject to material risks associated with doing business outside of the United States.
• The company is subject to risks associated with epidemics and pandemics, which could have a material adverse impact on the Companys business, financial condition, results of operations and cash flows.

Future Outlook

RYAM anticipates building upon its 2024 achievements by prioritizing value over volume in cellulose specialties, advancing its biomaterials strategy, and realizing production efficiencies. The company expects stronger second-half earnings in 2025 due to maintenance outages in the first half.

Management Comments

• 2024 marked a transformative chapter in our journey at RYAM, with the achievement of several strategic milestones that will position us well for the future, stated De Lyle Bloomquist, President and CEO of RYAM.
• We continued to strengthen our core High Purity Cellulose business and reduced our exposure to commodity markets.
• We made significant strides towards executing on our biomaterials strategy, and we improved our balance sheet while delivering outstanding financial results.
• Looking forward to 2025, we expect to build upon last years achievements by continuing to prioritize value over volume for our core cellulose specialties products, advancing our biomaterials strategy and realizing production efficiencies from strategic capital investments.
• However, this guidance remains subject to the potential for additional tariffs across our business segments, concluded Mr. Bloomquist.

Industry Context

RYAM's focus on cellulose specialties and biomaterials aligns with the industry trend towards higher-value, sustainable products. The company's efforts to reduce exposure to commodity markets reflect a strategy to mitigate cyclical risks. The biomaterials investments tap into the growing demand for green energy and renewable products.

Comparison to Industry Standards

• Comparible companies in the cellulose specialties market include Celanese and Eastman Chemical Company, which also focus on high-value applications of cellulose derivatives.
• RYAM's biomaterials strategy is similar to that of Stora Enso and UPM, which are investing in renewable materials and bio-based chemicals.
• The target ROE of 30% for biomaterials projects is competitive with industry standards for green energy investments.
• The two-year payback period for RYAM equity is aggressive, suggesting a focus on high-return projects.

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance and strategic growth.
• Employees: Opportunities for growth and development in higher-value business segments.
• Customers: Continued access to high-quality cellulose specialties and innovative biomaterials.
• Suppliers: Stable relationships and potential for increased business in growth areas.
• Creditors: Improved creditworthiness due to debt refinancing and stronger financial performance.

Next Steps

• Continue to prioritize value over volume for core cellulose specialties products.
• Advance the biomaterials strategy.
• Realize production efficiencies from strategic capital investments.
• Pursue all available legal and administrative remedies regarding the Fernandina Beach bioethanol facility project.
• Work on permitting, engineering and commercial agreements for crude tall oil and prebiotics facilities.
• Evaluate the construction and financing requirements for the AGE facility.
• The Company expects to receive the additional 15 million from SWEN in late 2025 and anticipates drawing on the term loans starting in 2026.

Key Dates